[ back to News ]

Concert Pharmaceuticals to Present at Canaccord Genuity Global Growth Conference on August 10, 2010

August 3, 2010

Lexington, MA ––Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Canaccord Genuity Global Growth Conference on Tuesday, August 10, 2010 at 4:00 p.m. Eastern Time.  The conference will be held August 10-12, 2010 at the InterContinental Boston in Boston, Massachusetts.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ to create novel and differentiated small molecule drugs containing deuterium. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development.  The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others.  In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines.  Founded in 2006, Concert has raised more than $110 million of venture and institutional capital.  For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]